Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Azacitidine 33venetoclax 10decitabine and cedazuridine drug combination 7Decitabine 7sabatolimab 3pevonedistat 3cedazuridine 3ON 01910 3spartalizumab 2glasdegib 2cc-486 2Panobinostat 2Cytarabine 2BI 6727 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2zanubrutinib 1triciribine 1tipifarnib 1terameprocol 1tapotoclax 1tagraxofusp 1ruxolitinib 1orludodstat 1navitoclax 1lonafarnib 1lintuzumab 1lenzilumab 1guadecitabine 1exatecan 1bisantrene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelomonocytic, Chronic × lonafarnib × Clear all
NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 3 Terminated
47 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡